Omnes Capital's investments

Sector 
Consumer goods
Entry Date 
2013
Business 
Co-Investment

Leading European ice cream company
The company is one of the leading manufacturer of ice cream in Europe.
Sector 
SaaS / Cloud
Entry Date 
2012
Business 
Venture Capital

Greenbureau

Digital customer relationship specialist.

Greenbureau is the first free-of-charge confidential and secure internet service that centralises bills for consumers. A pioneer of multi-brand digital customer relationships, Greenbureau saves on running costs for large groups by switching their customers over to digital billing, invoicing and online account management, etc.

Sector 
Mobile
Entry Date 
2012
Business 
Venture Capital

Mister Bell

Mobile advertising network

Mister Bell is a mobile performance based mobile advertising network founded in 2010.
With an exclusive inventory and unprecedented distribution capacity, Mister Bell is establishing itself as one of the leaders in mobile performance in Europe, Latin America and the Middle East. With its proprietary advertising tracking and re-targeting systems on smartphones and tablets, Mister Bell guarantees ROI levels to advertisers and offers innovative monetisation systems to content providers. Mister Bell is headquartered in Paris and now has subsidiaries in London, Berlin and Rio.

 

Sector 
Healthcare facilities
Entry Date 
2012
Business 
Co-Investment

Leading operator of private hospitals in Germany
Headquartered in Germany, the group counts among the leading operators of private hospitals in Germany.
Sector 
Business services
Entry Date 
2012
Business 
Mid-Cap Buyout & Growth Capital
Sales 
€200 million in 2014

Armatis

Leading contact centre and call centre operator in France.

Founded in 1989 by Denis Akriche, armatis-lc is a leading contact centre and call centre operator in France. armatis-lc, a leading player in the contact centre market in France, boasts 20 years’ experience and has focused on four areas: a full customer experience, a virtuous cycle of data use, international geographical coverage and a strong reputation for social responsibility.

Sector 
SaaS / Cloud
Entry Date 
2012
Business 
Venture Capital

Progexia

An alternative operator serving private health insurance companies

Progexia is an alternative operator serving private health insurance companies, wich provide solutions in the Cloud for reduce benefits payments costs.

Sector 
Infrastructure
Entry Date 
2012
Business 
Renewable Energy

Solar Infrastructure

Solar farm portfolio
Sector 
Business services
Entry Date 
2012
Business 
Small-Cap Buyout & Growth Capital
Sales 
€9 million in 2014

Mirabeau

Building security specialist

Mirabeau is a group formed of two SMEs specialised in building security.
Comtra designs, manufactures and distributes natural smoke extraction and aeration products. Unitecnic designs, manufactures and distributes access control products, harnessing RFID technology in particular. Thanks to its multidisciplinary research office (mechanics, electronics and networking), the Mirabeau group possesses patents and innovative solutions at the cutting edge of its markets. Its customers are professional distributors, joiners, locksmiths, installation contractors and façade specialists. Comtra and Unitecnic work on a number of flagship construction projects (head offices, 
museums, hospitals, stadia, etc.).

 

Sector 
Independent power producer
Entry Date 
2012
Business 
Renewable Energy

Abakus Solar

A leading, international system company for photovoltaics
Abakus solar AG was founded in 1995 and is a leading, international system company for photovoltaics with comprehensive technical competence ranging from the small power plant to the megawatt solar park. The main business areas of the company are the planning and turnkey installation of photovoltaic power plants, wholesale trading with top-class components and complete photovoltaic systems, as well as the technical operational management of solar power plants.
Sector 
Medical devices
Entry Date 
2011
Business 
Venture Capital

Pixium

Up-and-coming leader in bionic vision and vision restoration systems (VRS)

Pixium Vision was founded in December 2011 by Bernard Gilly, Professor José-Alain Sahel, and several highly renowned scientists from prestigious academic and technology institutions. The company develops innovative vision restoration systems (VRS) that are active medical devices. They can be implanted to treat blindness caused by degeneration of the photo-receptor cells of the retina. VRS stimulate the retina to produce a bionic vision and aim to significantly improve the independence, mobility and quality of life of patients who have lost their sight. Called IRIS® (in clinical trials) and PRIMA (under development), these VRS harness the latest advances in microelectronics/nanoelectronics, optronics, neurobiology and software. With the help of these technologies, Pixium Vision ultimately aims to provide a therapeutic solution delivering bionic vision as close as possible to normal vision.

“Within ten years, we can become the world leader in the market.”
BERNARD
GILLY
Executive Chairman
of Pixium Vision
Pixium Vision

A long-term view

In June 2014, Omnes Capital supported the initial public offering made by Pixium Vision, a start-up specialising in vision restoration systems (VRSs). The IPO was highly successful, as one would expect for a company at the leading edge of research into visual impairment. A month later, Bernard Gilly, head of Pixium Vision, confirmed its success, with a total of €39.5 million ultimately raised.
BERNARD GILLY
Executive Chairman of Pixium Vision

Disruptive innovation

Alexia Perouse (Partner at Omnes Capital) and Bernard Gilly first discussed vision restoration systems in the early 2000s. "VRSs aim to enable blind people to perceive shapes and movements, a really tremendous project. But their design came up against two hurdles, systems miniaturisation and real-time image transmission", explains Bernard Gilly. 

 

Pixium overcame these hurdles in 2011 when it launched IRIS (short for Intelligent Retinal Implant System), consisting of a pair of glasses with an integrated mini-camera linked to a pocket computer and a retinal implant that stimulates the brain cells. 

 

"It met all our criteria for investment: disruptive technology, a seasoned management team and a promising medtech sector", says Alexia Perouse. So in 2012, Omnes Capital invested €5 million.

BERNARD
GILLY
Executive Chairman
of Pixium Vision
What sets Pixium apart from its competitors?
Our technology. We are pioneers in VRSs working as artificial retinas. IRIS, our first implant, has between 50 and 150 electrodes and can be implanted under general anaesthetic in two hours. PRIMA, the next generation, will have more than one thousand wireless electrodes and will be implanted under local anaesthetic in just 30 minutes. Both are being developed by an international network of research scientists from the Vision Institute, Université Pierre-et- Marie-Curie and the universities of Stanford and Jerusalem.
What do you expect from your partnership with Omnes Capital?
Omnes Capital has always been a partner that assesses our decisions, our strategy and our new hires, such as Pierre Kemula (former head of Investor Relations at Ipsen) who joined us as CFO last June. Alexia Perouse and her team know our project intimately, as they do the biotechnology and medical devices markets in general. We are united by strong mutual trust, which also stems from our long-standing relationship with Alexia, whom I have known since 2000.
What are your ambitions for the next few years?
The market is structuring itself. Within ten years, we can become a world leader with IRIS and PRIMA, but also with our R&D work on optical nerve pathologies, such as glaucoma. Will this growth be achieved alone or as part of a major group following a buyout? Only time will tell.

Timeline

• 2011: Bernard Gilly founds Pixium Vision with a group of scientists working at the Vision Institute and Université Pierre-et-Marie-Curie
• 2012: The first funding round organised with Omnes Capital raises €23.5 million
• 2013: Clinical trials begin on IRIS
• 2014: The IPO raises €39.5 million
• 2015: Development of IRIS begins in the United-States
pixium-vision

Pages

NewsRoom
Press release
28 November 2017
OMNES UNVEILS ITS INVESTMENT STRATEGY FOR DEEP-TECH B2B START-UPS TO SUPPORT TECHNOLOGICAL BREAKTHROUGHS

OMNES UNVEILS ITS INVESTMENT STRATEGY FOR DEEP-TECH B2B START-UPS TO SUPPORT TECHNOLOGICAL BREAKTHROUGHS
Publication
Omnes Newsletter no 32: Edirotial by Fabien Prévost, CEO, Omnes
Press release
23 October 2017
Appointments within Omnes Capital:
Omnes Capital has promoted two Principals and three Associates and is welcoming one new Associate, a Director of Operations and a new Head of Human Resources.

Appointments within Omnes Capital: Omnes Capital has promoted two Principals and three Associates and is welcoming one new Associate, a Director of Operations and a new Head of Human Resources.
Press release
14 September 2017
Omnes Capital invests in Aero Negoce International (ANI) through an Owner Buy-Out (OBO)
Omnes Capital invests in Aero Negoce International (ANI) through an Owner Buy-Out (OBO)
Press release
26 July 2017
Omnes Capital completes primary LBO of the Geoxia Group's brands in the Nouvelle Aquitaine region (Maisons Clairlande, Les Demeures de la Côte d’Argent, Rouquié Constructions)
Omnes Capital completes primary LBO of the Geoxia Group's brands in the Nouvelle Aquitaine region (Maisons Clairlande, Les Demeures de la Côte d’Argent, Rouquié Constructions)
Publication
Omnes Capital Newsletter n°31: Green building news H1 2017

Pages